Targeting metallothionein for prognosis and treatment of breast cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 2, 2011, Pages 178-185

  Lai, Yiyang ^a   Yip, George W C ^a   Bay, Boon Huat ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biomarker; Breast cancer; Chemoresistance; Metallothionein; Molecular therapy; MT 1E; MT 2A; MT 3

Indexed keywords

BIOLOGICAL MARKER; ISOPROTEIN; METALLOPROTEIN; METALLOPROTEIN 4; METALLOTHIONEIN; METALLOTHIONEIN I; METALLOTHIONEIN II; METALLOTHIONEIN III; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; METALLOTHIONEIN; PATENTS AS TOPIC; PROGNOSIS; PROTEIN ISOFORMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79954525377     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211795328495     Document Type: Article

References (103)

1. National Cancer Institute. SEER Cancer Statistics Review. Available at: http://seer.cancer.gov/statfacts/html/breast.html (Accessed on January 27 2011).
2. Seow A, Koh WP, Chia KS, Shi LM, Lee HP, Shanmugaratnam K. Trends in Cancer Incidence in Singapore 1968-2002. Singapore Cancer Registry Report No.6:2004.
3. Rakha EA, Reis-Filho JS, Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 2010; 120: 293-308.
4. National Cancer Institute. Cancer Advances In Focus: Breast Cancer. Available at:http://www.cancer.gov/cancertopics/canceradvances-in-focus/breast (Accessed on: January 27 2011).
5. Kagi J. In: Suzuki KY, Imura N, Kimura M, Eds. Metallothionein III. Basel. Birkhauser 1993: pp. 29-55.
6. Coyle P, Philcox JC, Carey LC, Rofe AM. Metallothionein: The multipurpose protein. Cell Mol Life Sci 2002; 59: 627-47.
7. Kagi JH, Schaffer A. Biochemistry of metallothionein. Biochemistry 1988; 27: 8509-15.
8. Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 2003; 533: 201-9.
9. West AK, Stallings R, Hildebrand CE, Chiu R, Karin M, Richards RI. Human metallothionein genes: Structure of the functional locus at 16q13. Genomics 1990; 8: 513-8.
10. Stennard FA, Holloway AF, Hamilton J, West AK. Characterisation of six additional human metallothionein genes. Biochim Biophys Acta 1994; 1218: 357-65.
11. Shaw CF 3rd, Savas MM, Petering DH. Ligand substitution and sulfhydryl reactivity of metallothionein. Methods Enzymol 1991; 205: 401-14.
12. Maret W, Vallee BL. Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc Natl Acad Sci USA 1998; 95: 3478-82
13. Kelly EJ, Sandgren EP, Brinster RL, Palmiter RD. A pair of adjacent glucocorticoid response elements regulate expression of two mouse metallothionein genes. Proc Natl Acad Sci USA 1997; 94: 10045-50.
14. Lee DK, Carrasco J, Hidalgo J, Andrews GK. Identification of a signal transducer and activator of transcription (STAT) binding site in the mouse metallothionein-I promoter involved in interleukin-6-induced gene expression. Biochem J 1999; 337: 59-65.
15. Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmsdorf HJ, et al. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 1987; 49: 729-39.
16. Dalton T, Palmiter RD, Andrews GK. Transcriptional induction of the mouse metallothionein-I gene in hydrogen peroxide-treated Hepa cells involves a composite major late transcription factor/antioxidant response element and metal response promoter elements. Nucleic Acids Res 1994; 22: 5016-23.
17. Gunes C, Heuchel R, Georgiev O, Muller KH, Lichtlen P, Bluthmann H, et al. Embryonic lethality and liver degeneration in mice lacking the metal-responsive transcriptional activator MTF-1. EMBO J 1998; 17: 2846-54.
18. Koizumi S, Suzuki K, Ogra Y, Yamada H, Otsuka F. Transcriptional activity and regulatory protein binding of metalresponsive elements of the human metallothionein-IIA gene. Eur J Biochem 1999; 259: 635-42.
19. Andrews GK. Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem Pharmacol 2000; 59: 95-104.
20. Ohtsuji M, Katsuoka F, Kobayashi A, Aburatani H, Hayes JD, Yamamoto M. Nrf1 and Nrf2 play distinct roles in activation of antioxidant response element-dependent genes. J Biol Chem 2008; 283: 33554-62.
21. Mickleburgh I, Chabanon H, Nury D, Fan K, Burtle B, Chrzanowska-Lightowlers Z, et al. Elongation factor 1alpha binds to the region of the metallothionein-1 mRNA implicated in perinuclear localization-importance of an internal stem-loop. RNA 2006; 12: 1397-407.
22. Nury D, Chabanon H, Levadoux-Martin M, Hesketh J. An eleven nucleotide section of the 3'-untranslated region is required for perinuclear localization of rat metallothionein-1 mRNA. Biochem J 2005; 387: 419-28.
23. Palmiter RD. The elusive function of metallothioneins. Proc Natl Acad Sci USA 1998; 95: 8428-30.
24. Erickson JC, Sewell AK, Jensen LT, Winge DR, Palmiter RD. Enhanced neurotrophic activity in Alzheimer's disease cortex is not associated with down-regulation of metallothionein-III (GIF). Brain Res 1994; 649: 297-304.
25. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M. The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron 1991; 7: 337-47.
26. Quaife C, Hammer RE, Mottet NK, Palmiter RD. Glucocorticoid regulation of metallothionein during murine development. Dev Biol 1986; 118: 549-55.
27. Jin R, Chow VT, Tan PH, Dheen ST, Duan W, Bay BH. Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 2002; 23: 81-6.
28. Fan LZ, Cherian MG. Potential role of p53 on metallothionein induction in human epithelial breast cancer cells. Br J Cancer 2002; 87: 1019-26.
29. Mocchegiani E, Giacconi R, Cipriano C, Malavolta M. NK and NKT cells in aging and longevity: Role of zinc and metallothioneins. J Clin Immunol 2009; 29: 416-25.
30. Raymond AD, Gekonge B, Giri MS, Hancock A, Papasavvas E, Chehimi J, et al. Increased metallothionein gene expression, zinc, and zinc-dependent resistance to apoptosis in circulating monocytes during HIV viremia. J Leukoc Biol 2010; 88: 589-96.
31. Zatta P. Metallothioneins in Biochemistry and Pathology. World Scientific: New Jersey 2008.
32. Nagel WW, Vallee BL. Cell cycle regulation of metallothionein in human colonic cancer cells. Proc Natl Acad Sci USA 1995; 92: 579-83.
33. Jin R, Bay B, Tan P, Tan BK. Metallothionein expression and zinc levels in invasive ductal breast carcinoma. Oncol Rep 1999; 6: 871-5.
34. Sens MA, Somji S, Lamm DL, Garrett SH, Slovinsky F, Todd JH, et al. Metallothionein isoform 3 as a potential biomarker for human bladder cancer. Environ Health Perspect 2000; 108: 413-8.
35. El Sharkawy SL, Abbas NF, Badawi MA, El Shaer MA. Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions. J Clin Pathol 2006; 59: 1171-74.
36. Lim D, Jocelyn KM, Yip GW, Bay BH. Silencing the Metallothionein-2A gene inhibits cell cycle progression from G1-to S-phase involving ATM and cdc25A signaling in breast cancer cells. Cancer Lett 2009; 276: 109-17.
37. Rusetskaya NV, Lukyanova NY, Chekhun VF. Molecular profile and cell cycle in MCF-7 and MCF-7/Dox cells exposed to conventional and liposomal forms of doxorubicin. Exp Oncol 2009; 31: 140-3.
38. Yap X, Tan HY, Huang J, Lai Y, Yip GW, Tan PH, et al. Overexpression of metallothionein predicts chemoresistance in breast cancer. J Pathol 2009; 217: 563-70.
39. Maghdooni Bagheri P, Govaerts I, De Ley M. Role of metallothionein in differentiation of leukemia cells. Mol Biol Rep 2010. E Pub.
40. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
41. Fresno M, Wu W, Rodriguez JM, Nadji M. Localization of metallothionein in breast carcinomas. An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol 1993; 423: 215-9.
42. Bier B, Douglas-Jones A, Totsch M, Dockhorn-Dworniczak B, Bocker W, Jasani B, et al. Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant breast lesions. Breast Cancer Res Treat 1994; 30: 213-21.
43. Jin R, Bay BH, Chow VT, Tan PH, Dheen T. Significance of metallothionein expression in breast myoepithelial cells. Cell Tissue Res 2001; 303: 221-6.
44. Schmid KW, Ellis IO, Gee JM, Darke BM, Lees WE, Kay J, et al. Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast. Virchows Arch A Pathol Anat Histopathol 1993; 422: 153-9.
45. Dustch-Wicherek M, Popiela TJ, Klimek M, Rudnicka-Sosin L, Wicherek L, Oudinet JP, et al. Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and breast adeno-carcinoma. Neuro Endocrinol Lett 2005; 26: 567-74.
46. Gurel V, Sens DA, Somji S, Garrett SH, Weiland T, Sens MA. Post-transcriptional regulation of metallothionein isoform 1 and 2 expression in the human breast and the MCF-10A cell line. Toxicol Sci 2005; 85: 906-15.
47. Vasak M, Meloni G. In: Zatta P. Metallothioneins in biochemistry and pathology. New Jersey. World Scientific 2008: pp. 3-26.
48. Ostrakhovitch EA, Olsson PE, Jiang S, Cherian MG. Interaction of metallothionein with tumor suppressor p53 protein. FEBS Lett 2006; 580: 1235-8.
49. Huang M, Shaw IC, Petering DH. Interprotein metal exchange between transcription factor IIIa and apo-metallothionein. J Inorg Biochem 2004; 98: 639-48.
50. Cano-Gauci DF, Sarkar B. Reversible zinc exchange between metallothionein and the estrogen receptor zinc finger. FEBS Lett 1996; 386: 1-4.
51. Palmiter RD. Regulation of metallothionein genes by heavy metals appears to be mediated by a zinc-sensitive inhibitor that interacts with a constitutively active transcription factor, MTF-1. Proc Natl Acad Sci USA 1994; 91: 1219-23.
52. Bakka A, Endresen L, Johnsen AB, Edminson PD, Rugstad HE. Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein. Toxicol Appl Pharmacol 1981; 61: 215-26.
53. Satoh M, Cherian MG, Imura N, Shimizu H. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res 1994; 54: 5255-7.
54. Sens MA, Somji S, Garrett SH, Beall CL, Sens DA. Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis. Am J Pathol 2001; 159: 21-6.
55. Tai SK, Tan OJ, Chow VT, Jin R, Jones JL, Tan PH, et al. Differential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: Identification of a novel nonsilent metallothionein-1H mutant variant. Am J Pathol 2003; 163: 2009-19.
56. Piotrowski A, Benetkiewicz M, Menzel U, de Stahl TD, Mantripragada K, Grigelionis G, et al. Microarray-based survey of CpG islands identifies concurrent hyper-and hypomethylation patterns in tissues derived from patients with breast cancer. Genes Chromosomes Cancer 2006; 45: 656-67.
57. Scibetta AG, Santangelo S, Coleman J, Hall D, Chaplin T, Copier J, et al. Functional analysis of the transcription repressor PLU-1/JARID1B. Mol Cell Biol 2007; 27: 7220-35.
58. Friedline JA, Garrett SH, Somji S, Todd JH, Sens DA. Differential expression of the MT-1E gene in estrogen-receptor-positive and-negative human breast cancer cell lines. Am J Pathol 1998; 152: 23-7.
59. Jin R, Bay BH, Chow VT, Tan PH, Lin VC. Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer. Br J Cancer 2000; 83: 319-23.
60. McKenzie K, Sukumar S. In: Huff J, Boyd J, Barrett JC, Eds. Cellular and molecular mechanisms of hormonal carcinogenesis: Environmental Influences. New York. Wiley-Liss 1996: 183-209.
61. Yasaziji H, Gown AM, Sneige N. Detection of stromal invasion in breast cancer: The myoepithelial markers. Adv Anat Pathol 2000; 7: 100-9.
62. Jin R, Bay BH, Chow VT, Tan PH. Metallothionein 1F mRNA expression correlates with histological grade in breast carcinoma. Breast Cancer Res Treat 2001; 66: 265-72.
63. Jasani B, Schmid KW. Significance of metallothionein overexpression in human tumours. Histopathology 1997; 31: 211-4.
64. Abdel-Mageed A, Agrawal KC. Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther 1997; 4: 199-207.
65. Rao PS, Jaggi M, Smith DJ, Hemstreet GP, Balaji KC. Metallothionein 2A interacts with the kinase domain of PKCmu in prostate cancer. Biochem Biophys Res Commun 2003; 310: 1032-8.
66. Gurel V, Sens DA, Somji S, Garrett SH, Nath J, Sens MA. Stable transfection and overexpression of metallothionein isoform 3 inhibits the growth of MCF-7 and Hs578T cells but not that of T-47D or MDA-MB-231 cells. Breast Cancer Res Treat 2003; 80: 181-91.
67. Hayes DF, Bast RC, Desch CE, Fritsche H Jr., Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-66.
68. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
69. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 2004; 351: 2817-26.
70. Goulding H, Jasani B, Pereira H, Reid A, Galea M, Bell JA, et al. Metallothionein expression in human breast cancer. Br J Cancer 1995; 72: 968-72.
71. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-77.
72. Haerslev T, Jacobson K, Zedeler K. The prognostic significance of immunohistochemically detectable metallothionein in primary breast carcinomas. APMIS 1995; 103: 279-85.
73. Zhang R Zhang H, Wei H, Luo X. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis J Environ Pathol Toxicol Oncol 2000; 19: 95-7.
74. Oyama T, Take H, Hikino T, Iino Y, Nakajima T. Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. Oncology 1996; 53: 112-7.
75. Surowiak P, Matkowski R, Materna V, Gyorffy B, Wojnar A, Pudelko M, et al. Elevated metallothionein (MT) expression in invasive ductal breast cancer predicts tamoxifen resistance. Histol Histopathol 2005; 20: 1037-44.
76. Ioachim E, Kamina S, Demou A, Kontostolis M, Lolis D, Agnantis NJ. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Anticancer Res 1999; 19: 2133-9.
77. Bay BH, Jin R, Huang J, Tan PH. Metallothionein as a prognostic biomarker in breast cancer. Exp Biol Med (Maywood) 2006; 231: 1516-21.
78. Vazquez-Ramirez FJ, Gonzalez-Campora JJ, Hevia-Alvarez E, Fernandez-Santos JM, Rios-Martin JJ, Otal-Salaverri C, et al. Pglycoprotein, metallothionein and NM23 protein expressions in breast carcinoma. Pathol Res Pract 2000; 196: 553-9.
79. Erlander, M.G., Ma, X., Sgroi, D.C. Grading of breast cancer. US20090092973 (2009).
80. Erlander, M.G., Ma, X., Sgroi, D.C. Tumor grading and cancer prognosis. WO2009108215 (2009).
81. Badve, S., Nakshatri, H. Cancer therapy prognosis. US20100068717 (2010).
82. Cobleigh, M.A., Shak, S., Baker, J.B., Cronin, M.T. Gene expression markers for breast cancer prognosis. US20100222229 (2010).
83. Cree IA, Knight L, Di Nicolantonio F, Sharma S, Gulliford T. Chemosensitization of solid tumors by modulation of resistance mechanisms. Curr Opin Investig Drugs 2002; 3: 634-40.
84. Cutts SM, Swift LP, Rephaeli A, Nudelman A, Phillips DR. Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde. Curr Med Chem Anticancer Agents 2005; 5: 431-47.
85. Cutts SM, Parsons PG, Sturm RA, Phillips DR. Adriamycininduced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase. J Biol Chem 1996; 271: 5422-9.
86. Begleiter A, Leith MK. Activity of quinone alkylating agents in quinone-resistant cells. Cancer Res 1990; 50: 2872-6.
87. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-41.
88. Rharass T, Vigo J, Salmon JM, Ribou AC. New method for the detection of reactive oxygen species in anti-tumoural activity of adriamycin: A comparison between hypoxic and normoxic cells. Free Radic Res 2008; 42: 124-34.
89. Satoh M, Naganuma A, Imura N. Modulation of adriamycin toxicity by tissue-specific induction of metallothionein synthesis in mice. Life Sci 2000; 67: 627-34.
90. Yang M, Kroft SH, Chitambar CR. Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate. Mol Cancer Ther 2007; 6: 633-43.
91. Puca R, Nardinocchi L, Bossi G, Sacchi A, Rechavi G, Givol D, et al. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. Exp Cell Res 2009; 315: 67-75.
92. D'Orazi, G., Rechavi, G., Givol, D. Use of zinc in combination with chemotherapy for treating cancer. WO2009072120 (2009).
93. Magda, D., Sessler, J.L. Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer. US7528125 (2009).
94. Kiss, Z. Use of one or more metal carriers to selectively kill mammalian cells. US20100137557 (2010).
95. Knipp M. Metallothioneins and platinum(II) anti-tumor compounds. Curr Med Chem 2009; 16: 522-37.
96. Karotki AV, Vasak M. Interaction of metallothionein-2 with platinum-modified 5'-guanosine monophosphate and DNA. Biochemistry 2008; 47: 10961-9.
97. Lichtlen P, Schaffner W. Putting its fingers on stressful situations: The heavy metal-regulatory transcription factor MTF-1. Bioessays 2001; 23: 1010-7.
98. Feng, P. Potent inhibitory effect of zinc in combination with sulforaphane on cancer cell growth. US20100183740 (2010).
99. Aggarwal, B.B., Singh, S. Selective inhibitors of Nuclear Factor KappaB activation and uses thereof. US20090111754 (2009).
100. Tolman, G.L. Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules. US4732864 (1988).
101. Eckhardt, S.G., Pitts, T.M., Tan, A.C. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors. US20100240665 (2010).
102. Hillman, J.L., Goli, S.K. DNA encoding human metallothionein. US5955428 (1997).
103. Berezin, V., Bock, E., Penkowa, M. Metallothionein-derived peptide fragment. US20100166759 (2010).